Brookline Capital Reiterates Adial Pharmaceuticals (ADIL) Buy Recommendation
Fintel reports that on July 11, 2023, Brookline Capital reiterated coverage of Adial Pharmaceuticals (NASDAQ:ADIL) with a Buy recommendation.
Symbol | Last Price | Change | % Change |
---|---|---|---|